Acute Kidney Injury in Lymphoma: A Single Centre Experience

Table 2

Univariate analysis of factors associated with progression of AKI (𝑛=365).

	AKI, 𝑛=116	No AKI, 𝑛=249	𝑃 value
Age, in years	53.7 ± 15.5	48.7 ± 16.5	0.005
Gender
Male	82 (70.7)	180 (72.3)	0.75
Female	34 (29.3)	69 (27.7)
Hospital stay, median (range)	3 (1–17)	3 (1–14)	0.62*
Baseline Cr, median (range)	0.8 (0.4–2.6)	0.8 (0.4–11.1)	0.39*
Maximum Cr, median (range)	2 (0.9–11.3)	1 (0.6–25.9)	<0.001*
Stage of lymphoma
I	4 (9.3)	9 (9.1)	0.17
II	7 (16.3)	32 (32.3)
III	10 (23.3)	24 (24.2)
IV	22 (51.2)	34 (34.3)
Diuretics	24 (20.7)	16 (6.4)	<0.001
Vancomycin	17 (14.7)	17 (6.8)	0.02
Amphotericin B	7 (6)	9 (3.6)	0.28
Aminoglycosides	11 (9.5)	3 (1.2)	<0.001
Mechanical ventilation	12 (10.3)	11 (4.4)	0.03
Vasopressor	16 (13.8)	15 (6)	0.01
Chemotherapy
R-CHOP	26 (22.4)	68 (27.3)	0.31
CHOP	26 (22.4)	60 (24.1)	0.79
R-CVP	13 (11.2)	8 (3.2)	0.004
CVP	8 (6.9)	11 (4.4)	0.32
ABVD	12 (10.3)	42 (16.9)	0.11
DHAP	17 (14.7)	16 (6)	0.009
Sepsis	38 (57.6)	26 (17.2)	<0.001
Tumor lysis	18 (15.5)	10 (4.0)	<0.001
Hospital stay
≤7 days	72 (62.1)	202 (81.1)	<0.001
>7 days	44 (37.9)	47 (18.7)
Mortality	17 (14.7)	17 (6.8)	0.02

∗Mann-Whitney 𝑈 test.